57965-30-7

Usage

Uses

Used in Pharmaceutical Industry:
(S)-(-)-Thiolactic Acid is used as an intermediate for the synthesis of (R)-(+)-Thiolactomycin (T350880), a natural product inhibitor of β-Ketoacyl-AcpM Synthase A (KasA). This application is significant because it targets the inhibition of mycolic acid synthesis, which is a major cell wall component of Mycobacterium tuberculosis, a bacterium responsible for tuberculosis.
Additionally, (S)-(-)-Thiolactic Acid is used as an inhibitor of D-Aspartate oxidase (DDO), an enzyme involved in the metabolism of D-aspartate. This application is relevant in the development of drugs targeting neurological disorders and other conditions related to D-aspartate metabolism.

Upstream product

• 7474-05-7 (R)-2-chloropropionic acid 
• 32644-15-8 (S)-2-bromopropanoic acid 

Downstream Products

• 119383-02-7 (-)-trans-3,5-dimethyl-2-(pyridin-3-yl)-thiazolidin-4-one 
• 119383-00-5 (2R,5S)-(+)-cis-3,5-Dimethyl-2-(3-pyridyl)thiazolidin-4-one 
• 20461-87-4 2-methyl-3-thiapentanoic acid 
• 476371-85-4 2-tert-butyl-4-methyl-1,3-oxathiolan-5-one 
• 33178-97-1 (S)-2-(methylthio)propanoic acid 

Relevant academic research and scientific papers

COMPOUNDS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES

The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

THIOPHENE DERIVATIVES AS PPAR AGONISTS I

The invention discloses compounds of formula (I); wherein: R is a carboxylic acid or a derivative thereof; R1 is alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkylthio, halo or trihalomethyl; R2 is aryl, heteroaryl, arylalkyl or heteroarylalkyl; R3 is H or F; and L is a linking group comprising a chain of from 2 to 8 atoms linking R and the carbonyl group (A); and pharmaceutically acceptable derivatives thereof, useful for treating disorders mediated by peroxisome-proliferator-activated receptor (PPAR) subtype δ (PPARδ). The compounds of the invention are therefore useful in the treatment of metabolic syndrome, obesity, type-II diabetes, dyslipidemia, wound healing, inflammation, neurodegenerative disorders and multiple sclerosis.